DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France.
Ann Clin Transl Neurol
; 8(8): 1738-1744, 2021 08.
文章
在 英语
| MEDLINE | ID: covidwho-1300348
ABSTRACT
We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39-3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18-0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon.
全文:
可用
采集:
国际数据库
资料库:
MEDLINE
主要主题:
Interferons
/
Antibodies, Monoclonal, Humanized
/
Rituximab
/
COVID-19
/
Immunologic Factors
/
Multiple Sclerosis
研究类型:
队列研究
/
实验研究
/
观察性研究
/
预后研究
/
随机对照试验
/
点评
限制:
成人
/
女性
/
人类
/
男性
/
中年
国家/地区名称主题:
欧罗巴
语言:
英语
期刊:
Ann Clin Transl Neurol
年:
2021
类型:
文章
所属国家:
Acn3.51408
相关文档
MEDLINE
...
LILACS
LIS